S. Majumdar

First name
S.
Middle name
R.
Last name
Majumdar
MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D., Bhagra, S., Jhund, P. S., et al. (2010). Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care. http://doi.org/10.2337/dc09-2227
Padwal, R. S., Klarenbach, S. W., Wang, X., Sharma, A. M., Karmali, S., Birch, D. W., & Majumdar, S. R. (2013). A simple prediction rule for all-cause mortality in a cohort eligible for bariatric surgery. JAMA Surg. http://doi.org/10.1001/jamasurg.2013.3953
Gamble, J. M., Thomas, J. M., Twells, L. K., Midodzi, W. K., & Majumdar, S. R. (2016). Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users. Medicine (Baltimore). http://doi.org/10.1097/md.0000000000003995
Gamble, J. M., Chibrikov, E., Twells, L. K., Midodzi, W. K., Young, S. W., MacDonald, D., & Majumdar, S. R. (2017). Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol. http://doi.org/10.1016/s2213-8587(16)30316-3
Gamble, J. M., Donnan, J. R., Chibrikov, E., Twells, L. K., Midodzi, W. K., & Majumdar, S. R. (2018). The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study. Diabetes Res Clin Pract. http://doi.org/10.1016/j.diabres.2017.12.008
Gamble, J. M., Chibrikov, E., Midodzi, W. K., Twells, L. K., & Majumdar, S. R. (2018). Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink. BMJ Open. http://doi.org/10.1136/bmjopen-2018-023830
Gamble, J. M., Donnan, J. R., Chibrikov, E., Twells, L. K., Midodzi, W. K., & Majumdar, S. R. (2018). Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes. Sci Rep. http://doi.org/10.1038/s41598-018-33483-y